SML0225

LY255582

≥98% (HPLC)

• 别名: (3R,4R)-3,4-Dimethyl-1-[(3S)-3-hydroxy-3-cyclohexyl-propyl]-4-(3-hydroxyphenyl)piperidine, (aS,3R,4R)-a-Cyclohexyl-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinepropanol, LY-255582
• 经验公式（希尔记法）: C₂₂H₃₅NO₂
• CAS号: 119193-09-8
• 分子量: 345.52
• MDL號碼: MFCD00878181
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329825244
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: desiccated
• 顏色: white to beige
• 溶解度: DMSO: ≥15 mg/mL
• 起源: Eli Lilly
• 儲存溫度: 2-8°C
• SMILES 字串: C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c3cccc(O)c3
• InChI: 1S/C22H35NO2/c1-17-16-23(13-11-21(25)18-7-4-3-5-8-18)14-12-22(17,2)19-9-6-10-20(24)15-19/h6,9-10,15,17-18,21,24-25H,3-5,7-8,11-14,16H2,1-2H3/t17-,21-,22+/m0/s1
• InChI 密鑰: LVVHEFJXPXAUDD-BULFRSBZSA-N

说明

應用

LY255582 may be used in opioid receptor-mediated cell signaling studies.

生化／生理作用

LY255582 inhibits the diet-associated increases in mesolimbic dopamine levels and reduces the consumption of highly-palatable food intake.

LY255582 is a centrally active opioid receptor antagonist (defined as an inverse agonist in 2011 JPET paper) that inhibited weight gain in obese Zucker rats over 30 days. It is more that 5-fold selective for mu opioid receptor compared to kappa opioid receptors and 13-fold selective over delta opioid receptors.

特點和優勢

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable